Abstract: Objective To analyze the effect of dyslipidemia on the liver function after the first chemotherapy in breast cancer patients. Methods A total of 814 patients with breast cancer in our hospital were collected. Patients were divided into the dyslipidemia group (n=456) and the normal blood lipid group (n=358) according to their blood lipid before the first chemotherapy. The occurrence of abnormal liver function after the chemotherapy was compared between the two groups. According to blood lipids before chemotherapy, patients with abnormal liver function after chemotherapy (n=268) were divided into the mixed dyslipidemia group (n=16), the non-mixed dyslipidemia group (n=157) and the normal lipid group (n= 95). The alanine transaminase (ALT) levels after chemotherapy were compared between the three groups. According to the changes of blood lipid indexes before and after chemotherapy, all the patients were divided into the unstable blood lipid group (n=723) and the stable blood lipid group (n=91). The ALT levels after chemotherapy were compared between the two groups. Results There were no significant differences in age, body mass index (BMI), surgical history, chemotherapy regimen, and combined trastuzumab and ALT level before the first chemotherapy between the dyslipidemia group and the normal lipidemia group. Compared with the normal group, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL-C) were significantly increased in the dyslipidemia group, while the levels of high density lipoprotein (HDL-C) were significantly decreased (P＜0.01). The incidence of abnormal liver function after chemotherapy was higher in the dyslipidemia group (P＜0.01). After chemotherapy, the ALT level was significantly higher in the mixed dyslipidemia group than that in the non-mixed dyslipidemia group and the no dyslipidemia group (P＜0.01). After chemotherapy, the ALT level was significantly higher in the unstable blood lipid group than that in the stable blood lipid group (P＜0.05). Conclusion Breast cancer patients with lipid metabolism disorders are more likely to develop liver dysfunction after chemotherapy.

Key words: breast neoplasms, dyslipidemias, hepatic insufficiency, antineoplastic combined chemotherapy protocols